Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-07

Integration of in vitro approaches to predict drug metabolism and interactions in man in development of pharmaceuticals

Objetivo

To integrate in vitro tests or models, based on human liver-derived systems. for predicting the metabolism and metabolic interactions of drugs and chemicals which are likely to occur following their exposure in man and compare these with results in vivo.

Detailed knowledge of the metabolism of pharmaceuticals is essential as early as possible in the research and development process, for two main reasons. The metabolism of drugs is generally the major determinant of their pharmacokinetic behaviour, interindividual variability and interactions with other compounds, all factors that complicate drug treatment. Differences in metabolism are also very often responsible for difficulties in extrapolating from a toxicology test species to humans, which can be a serious obstacle in drug testing and development.
A large number of approaches, based largely, but not solely on human-derived systems, for the prediction of drug metabolism are under development, although not all areas are as well advanced as some. The project will involve the selection or development of suitable model substances and reagents which will be used to define rigorously the various candidate in vitro methods and approaches, the application of the most promising methods and approaches to existing drugs and substances under development, i.e. "real" compounds from the participating industrial laboratories, and a comparison of the predictive power of these approaches to metabolism in vivo, determined in volunteers. The likely outcome is the identification of suitable tests, and the development of an integrated approach to the prediction of the metabolism of drugs. This could be used in drug discovery, in the design and execution of toxicity tests and of early clinical trials.
Other major tangible benefits will accrue, such as a decrease in the cost of drug development and acceleration of the process, because clinical studies could be targeted on the basis of in vitro results. The project will help to reduce the number of animals required currently in the preclinical development of pharmaceuticals.

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

University of Oulu
Aportación de la UE
Sin datos
Dirección
52 D,KAJAANINTIE
90220 OULU
Finlandia

Ver en el mapa

Coste total
Sin datos

Participantes (11)